Julian Harrison Analyst Performance

Managing Director at BTIG Research

Julian Harrison is a stock analyst at BTIG Research in the medical sector, covering 16 publicly traded companies. Over the past year, Julian Harrison has issued 20 stock ratings, including buy and hold recommendations. While full access to Julian Harrison's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Julian Harrison's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 23 Last 3 Years
Buy Recommendations: 95.45% 21 Buy Ratings
Companies Covered: 16 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	95.5%	21 ratings
Hold	4.5%	1 ratings
Sell	0.0%	0 ratings

Out of 22 total stock ratings issued by Julian Harrison at BTIG Research, the majority (95.5%) have been Buy recommendations, followed by 4.5% Hold.

Best & Worst Calls

Best Call
00.0%
PTGX
Apr 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
AURA
Oct 2024
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	16 companies

Julian Harrison, an analyst at BTIG Research, currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 16 companies	100.0%

Julian Harrison of BTIG Research specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 12 companies	75.0%
MED - DRUGS 4 companies	25.0%

About Julian Harrison

Julian Harrison is a Managing Director and BTIG Biotechnology Analyst. Prior to BTIG, Julian was a Senior Analyst at Tekla Capital Management where he covered small- to large-cap biotechnology and pharmaceutical companies. Previously, he was a Clinical and Translational Research Assistant at Hospital for Special Surgery. Julian earned a BS in biology from Cornell University and an MS in health economics from Weill Cornell Medical College.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CLYM Climb Bio	10/16/2025	Reiterated Rating	$1.94	$8.00	Buy
TVRD Tvardi Therapeutics	10/13/2025	Lower Price Target	$6.48	$15.00	Buy
JBIO Jade Biosciences	10/9/2025	Initiated Coverage	$9.08	$28.00	Buy
APGE Apogee Therapeutics	10/9/2025	Reiterated Rating	$50.85	$115.00	Buy
JBIO Jade Biosciences	10/9/2025	Initiated Coverage	$9.40	$28.00	Buy
ABVX Abivax	10/6/2025	Boost Price Target	$86.67	$120.00	Buy
CLYM Climb Bio	9/30/2025	Boost Price Target	$1.99	$8.00	Buy
MLTX MoonLake Immunotherapeutics	9/29/2025	Downgrade	$61.99	$85.00	Neutral
ORKA Oruka Therapeutics	9/29/2025	Reiterated Rating	$15.20	$56.00	Buy
AVTX Avalo Therapeutics	9/29/2025	Reiterated Rating	$13.02	$40.00	Buy
CLYM Climb Bio	9/22/2025	Reiterated Rating	$2.32	$7.00	Buy
NKTR Nektar Therapeutics	9/19/2025	Reiterated Rating	$58.76	$100.00	Buy
RZLT Rezolute	9/18/2025	Reiterated Rating	$7.71	$17.00	Buy
ORKA Oruka Therapeutics	9/17/2025	Boost Price Target	$16.21	$56.00	Buy
SYRE Spyre Therapeutics	9/16/2025	Reiterated Rating	$14.84	$70.00	Buy
MAZE Maze Therapeutics	9/12/2025	Boost Price Target	$24.80	$37.00	Buy
CGEM Cullinan Therapeutics	9/10/2025	Reiterated Rating	$6.47	$32.00	Buy
ABVX Abivax	9/9/2025	Reiterated Rating	$90.00	$112.00	Buy
MAZE Maze Therapeutics	9/2/2025	Initiated Coverage	$14.49	$30.00	Buy
TBPH Theravance Biopharma	6/27/2025	Boost Price Target	$11.20	$25.00	Buy
AURA Aura Biosciences	10/18/2024	Boost Price Target	$11.25	$24.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.